Conexeu Sciences Inc. filed a Form 8-K to disclose unregistered sales of equity securities that exceeded 5% of its outstanding shares between June 18 and September 4, 2026. The company issued an aggregate of 1,448,368 common stock shares and 202,500 warrants. Key transactions include the issuance of 762,608 shares for $1,753,998.40 via warrant exercises on September 4, and 202,500 warrants plus 202,500 shares for approximately $162,202.50 on June 18. Additional issuances involved consulting and board agreements with share counts ranging from 1,601 to 70,000 at deemed prices between $2.30 and $13.96. Conexeu Sciences Inc. operates in the biotechnology industry, focusing on drug discovery.

Conexeu Sciences Inc. announced the completion of the P.R.O.O.F. phase of its CXU™ platform preclinical program, demonstrating successful tissue restoration in both small-volume facial and large-volume subcutaneous models. The 12-month study met performance benchmarks for injectability and volumizing performance, supporting the company's planned 510(k) regulatory submission for wound care in Q1 2027. Conexeu Sciences Inc. is a biotechnology company developing a flowable collagen platform for medical aesthetics and wound care applications.

Conexeu Sciences Inc. issued 416,667 shares of common stock on June 4, 2026, following the exercise of warrants under its Incentive Program, generating approximately $166,667 in gross proceeds. As part of this program, the company issued 416,667 additional Incentive Warrants to the holder, which allow for the purchase of one share of common stock at $2.30 per share for 36 months. Additionally, on June 8, 2026, the company issued 100,000 shares via the exercise of performance warrants for $100. Following these transactions, total outstanding common stock reached 26,758,330 shares. Conexeu Sciences Inc. is a science-based company focused on developing therapeutic solutions.